Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer

NCT03917082 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT03917082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03917082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 23, 2019
Completion date
May 1, 2029
Enrollment
290 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, hormone receptor positive tumor